Please share this information with friends and fellow investors alike. We have an otc stock that will not R/S, has no more convertible debt and will not take on any more(per CEO), an excellent and experienced management team, a transparent leader who has shown integrity so far in all situations(favorable or not), and industry contacts built in via years of combined experience on the part of the team. We have a newly renovated factory in China with equipment. We have a CEO looking for acquisitions and a promise of a significant share buyback should they go through. And, on the horizon, there are untold potential purchase orders that may only be a conversation or two away. In brief summary of the antecedent cataloging of information, this means: no convertible notes/debt, no dilution by way of conversion, transparency and communication, possible acquisition(s) and potential share buyback, credentialed management/team, a factory with machinery and raw materials, and profitability soon to follow as purchase orders will inevitably come in over time.
$TPAC Business Plan (pdf.):
Please share this information with friends and fellow investors alike. We have an otc stock that will not R/S, has no more convertible debt and will not take on any more(per CEO), an excellent and experienced management team, a transparent leader who has shown integrity so far in all situations(favorable or not), and industry contacts built in via years of combined experience on the part of the team. We have a newly renovated factory in China with equipment. We have a CEO looking for acquisitions and a promise of a significant share buyback should they go through. And, on the horizon, there are untold potential purchase orders that may only be a conversation or two away. In brief summary of the antecedent cataloging of information, this means: no convertible notes/debt, no dilution by way of conversion, transparency and communication, possible acquisition(s) and potential share buyback, credentialed management/team, a factory with machinery and raw materials, and profitability soon to follow as purchase orders will inevitably come in over time.
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Nvidia's Major $500 Million Investment in Wayve for AI Expansion
Nvidia Invests $500 Million in Wayve Nvidia, known for its advanced AI technologies, is in discussions to invest a substantial $500 million into the U.K.-based autonomous driving startup Wayve. This move marks a significant step for Nvidia as it seeks to deepen its involvement in the rapidly evolving artificial intelligence sector. Strategic Importance of the Investment...
Continue Reading
Vortex Companies Enhances Leadership with Key Promotions
Elevating Leadership at Vortex Companies Vortex Companies, known for its rapid growth in the trenchless infrastructure rehabilitation sector, has recently made significant leadership changes with the promotions of Jonathan Thomas and Connor Mathis. Thomas steps into the role of Senior Regional Vice President for the Coastal Region, while Mathis ascends to Regional Vice...
Continue Reading
Scilex Holding Company Receives FDA Acknowledgment for ELYXYB
Scilex Holding Company’s FDA Milestone with ELYXYB Scilex Holding Company, based in Palo Alto, California, has gained significant recognition with the U.S. FDA's acknowledgment of their Supplemental New Drug Application (SNDA) for ELYXYB. This marks a substantial step forward for the company, which is dedicated to creating and advancing non-opioid pain management...
Continue Reading
Bio-Techne Expands AI-Driven Protein Portfolio
Advanced Proteins in the Spotlight Bio-Techne’s latest move is creating some serious buzz in the life sciences scene. They're not just talking the talk but walking the walk by expanding their R&D Systems AI-Engineered Designer Protein portfolio. What's the big news? They've engineered heat-stable and hyperactive proteins that promise to shake up fibroblast growth factor...
Continue Reading
PolyPid's D-PLEX100 Trial Results Revolutionize Infection Prevention
Groundbreaking Advances in Surgical Infection Prevention PolyPid Ltd. has made headlines recently, unveiling remarkable topline results from their pivotal SHIELD II Phase 3 trial. This innovative study showcased D-PLEX100, a major breakthrough in preventing surgical site infections (SSIs), showing statistically significant reductions in both primary and secondary...
Continue Reading